Coya Therapeutics, Inc.
COYA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001835022
No open-market purchases or sales by Coya Therapeutics, Inc. insiders were filed in the last 90 days; 51 institutions reported holding it in 13F filings for Q3 2026, worth $36.6M in total; Greenlight Capital is the only superinvestor holding it.
Key figures
- Market capClose on Nov 19, 2026
- $69.9M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ3 2026, −2 vs. previous quarter
- 51
- 13F valueReported value at the end of Q3 2026
- $36.6M
- Superinvestors holdingAt the end of Q3 2026
- 1
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $7.95M
- +123.6% year over year
- Net income, FY2025
- -$21.2M
- No comparable prior period
- Free cash flow, FY2025
- –
- No comparable prior period
- Revenue, Q3 FY2026
- $234.1K
- −93.4% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $21.2M (267.1% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 1.41M
- Shares sold short
- Change
- +156.1K
- +12.4% vs. previous
- Days to cover
- 11.89
- At average daily volume
Superinvestors holding COYA, Q3 2026
Go to the superinvestors tab1 superinvestor reports holding Coya Therapeutics, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Greenlight Capital
David Einhorn
0.3%
Coya Therapeutics, Inc.'s share of the portfolio
- Shares
- 2,335,540
- Value
- $11.7M
Latest insider trades
See all insider tradesOpen-market purchases and sales by Coya Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 14, 2024 (view filing) | Nov 14 | Same day | Snyder David SChief Financial Officer | PPurchaseCommon Stock, par value $0.0001 per share | +1.80K | $7.19 | +$12.9K | +25.7%8.80K after | |
| Nov 13, 2024 (view filing) | Nov 13 | Same day | Swaminathan ArunChief Executive Officer | PPurchaseCommon Stock, par value $0.0001 per share | +5.00K | $7.36 | +$36.8K | +100.0%10.0K after | |
| Nov 12, 2024 (view filing) | Nov 11 | 1 day | Grossman FredChief Medical Officer | PPurchaseCommon Stock, par value $0.0001 per share | +2.71K | $7.37 | +$20.0K | New position2.71K after | |
| Nov 12, 2024 (view filing) | Nov 11 | 1 day | Swaminathan ArunChief Executive Officer | PPurchaseCommon Stock, par value $0.0001 per share | +5.00K | $7.34 | +$36.7K | New position5.00K after | |
| Mar 5, 2024 (view filing) | Aug 22, 2023 | 196 daysLate | Lee AnnDirector | PPurchaseCommon Stock, par value $0.0001 per share | +1.00K | $3.62 | +$3.62K | +6.1%17.5K after | |
| Jan 4, 2023 (view filing)8:30 AM ET | Jan 3 | 1 day | Lee AnnDirector | PPurchaseCommon Stock, par value $0.0001 per share | +10.0K | – | – | New position10.0K after | |
| Jan 4, 2023 (view filing)8:30 AM ET | Jan 3 | 1 day | Lee AnnDirector | PPurchaseCommon Stock, par value $0.0001 per share | +5.00K | – | – | –9.48K after | Derivative |
| Jan 4, 2023 (view filing) | Jan 3 | 1 day | Berman HowardChief Executive Officer | PPurchaseCommon Stock, par value $0.0001 per share | +10.0K | – | – | New position10.0K after | From original |
| Jan 4, 2023 (view filing) | Jan 3 | 1 day | Berman HowardChief Executive Officer | PPurchaseCommon Stock, par value $0.0001 per share | +5.00K | – | – | –5.00K after | From originalDerivative |
| Jan 4, 2023 (view filing) | Jan 3 | 1 day | Hepner AdrianChief Medical Officer | PPurchaseCommon Stock, par value $0.0001 per share | +10.0K | – | – | New position10.0K after |
Top 10 13F holders, Q3 2026
See all 51 holdersThe largest institutional positions in Coya Therapeutics, Inc. at the end of Q3 2026; share changes are against Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| DME Capital Management, LPSuperinvestorGreenlight Capital | 2,335,540 | $11.7M | 0.33% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 852,751 | $4.27M | 0.00% | +10,531+1.3% | Added |
| AIGH Capital Management LLC | 631,912 | $3.17M | 0.36% | 00.0% | Unchanged |
| Alyeska Investment Group, L.P. | 400,000 | $2.00M | 0.01% | −400,000−50.0% | Reduced |
| CM Management, LLC | 400,000 | $2.00M | 1.34% | 00.0% | Unchanged |
| Private Management Group Inc | 380,876 | $1.91M | 0.05% | −3,341−0.9% | Reduced |
| Marshall Wace, LLP | 323,849 | $1.62M | 0.00% | +74,056+29.6% | Added |
| Prosight Management, LP | 229,600 | $1.15M | 0.22% | +59,600+35.1% | Added |
| Geode Capital Management, LLC | 211,036 | $1.06M | 0.00% | −17,207−7.5% | Reduced |
| Dimensional Fund Advisors LP | 169,458 | $849.1K | 0.00% | +13,541+8.7% | Added |
Holders of 5% or more of COYA
See all 2 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Coya Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| DME Capital Management, LPSuperinvestorGreenlight Capital | 13G/A | 9.90%1.65M shares | – | Feb 14, 20251 filing | Feb 14, 2025 | SEC |
| Dr. Reddy's Laboratories, Inc. | 13G | 9.70%2.27M shares | New | Mar 12, 20261 filing | Mar 12, 2026 | SEC |